Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73798 | 1.00 | THRA (0.43) | THRATHRBALOX5PTGS2HTR1A | |
| SCHEMBL12090288 | 1.00 | THRA (0.43) | THRATHRBALOX5PTGS2HTR1A | |
| SCHEMBL14092096 | 0.95 | THRA (0.49) | THRATHRBALOX5PTGS2HTR1A | |
| SCHEMBL12195800 | 0.87 | HTR1A (0.43) | THRATHRBALOX5PTGS2HTR1A | |
| SCHEMBL75748 | 0.87 | HTR1A (0.43) | THRATHRBALOX5PTGS2HTR1A | |
| SCHEMBL75741 | 0.87 | HTR1A (0.43) | THRATHRBALOX5PTGS2HTR1A | |
| SCHEMBL73995 | 0.86 | TAAR1 (0.45) | THRATHRBHTR1AADRA2AADRA2B | |
| SCHEMBL74606 | 0.86 | TAAR1 (0.45) | THRATHRBHTR1AADRA2AADRA2B | |
| SCHEMBL10056778 | 0.86 | TAAR1 (0.45) | THRATHRBHTR1AADRA2AADRA2B | |
| SCHEMBL14092090 | 0.84 | THRA (0.42) | THRATHRBALOX5PTGS2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9493505-B2 | Macrocyclic modulators of the ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | MALLINCKRODT LLC | 2015-05-28 | — | — | US | disclosed |
| US-8921521-B2 | Macrocyclic modulators of the Ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. (CA) | 2013-08-15 | — | — | US | disclosed |
| US-8497242-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2013-07-30 | — | — | US | disclosed |
| US-8450268-B2 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-8334256-B2 | Pharmaceutical salts of macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2012-12-18 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-RE42624-E1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2011-08-16 | — | — | US | disclosed |
| US-RE42013-E1 | Macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2010-12-28 | — | — | US | disclosed |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | THRA 414/4885THRB 521/4885ALOX5 3956/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | THRA 77/4885THRB 111/4885ALOX5 2868/4885 |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | THRA 506/4885THRB 670/4885ALOX5 3852/4885 |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | THRA 77/4885THRB 111/4885ALOX5 2868/4885 |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | THRA 77/4885THRB 111/4885ALOX5 2868/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | THRA 71/4885THRB 106/4885ALOX5 2051/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | THRA 506/4885THRB 670/4885ALOX5 3852/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | THRA 414/4885THRB 521/4885ALOX5 3956/4885 |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GIPR, GHRHR | THRA 77/4885THRB 111/4885ALOX5 2868/4885 |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | THRA 77/4885THRB 111/4885ALOX5 2868/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | THRA 71/4885THRB 106/4885ALOX5 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.